Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials

Cabotegravir plus rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of human immunodeficiency virus-1 (HIV-1) virologic suppression. This post hoc analysis summarizes CAB + RPV LA results by baseline body mass index (BMI) category among phase...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases 2024-07, Vol.230 (1), p.e34-e42
Hauptverfasser:	Elliot, Emilie R, Polli, Joseph W, Patel, Parul, Garside, Louise, Grove, Richard, Barnett, Vincent, Roberts, Jeremy, Byrapuneni, Sri, Crauwels, Herta, Ford, Susan L, Van Solingen-Ristea, Rodica, Birmingham, Eileen, D'Amico, Ronald, Baugh, Bryan, van Wyk, Jean
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anti-HIV Agents - administration & dosage Anti-HIV Agents - adverse effects Anti-HIV Agents - pharmacokinetics Anti-HIV Agents - therapeutic use Body Mass Index Diketopiperazines Drug Therapy, Combination Female HIV Infections - drug therapy HIV Infections - virology HIV-1 - drug effects Humans Male Middle Aged Pyridones - administration & dosage Pyridones - adverse effects Pyridones - pharmacokinetics Rilpivirine - administration & dosage Rilpivirine - adverse effects Rilpivirine - pharmacokinetics Rilpivirine - therapeutic use RNA, Viral - blood Treatment Outcome Viral Load - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Cabotegravir plus rilpivirine (CAB + RPV) is a guideline-recommended long-acting (LA) injectable regimen for the maintenance of human immunodeficiency virus-1 (HIV-1) virologic suppression. This post hoc analysis summarizes CAB + RPV LA results by baseline body mass index (BMI) category among phase 3/3b trial participants. Data from CAB + RPV-naive participants receiving every 4 or 8 week dosing in FLAIR, ATLAS, and ATLAS-2M were pooled through week 48. Data beyond week 48 were summarized by study (FLAIR through week 96 and ATLAS-2M through week 152). HIV-1 RNA
ISSN:	0022-1899 1537-6613 1537-6613
DOI:	10.1093/infdis/jiad580